Tuesday, May 23, 2017
Dr. Erol Onel is a medical practitioner with extensive experience in fields ranging from reproductive health to oncology and clinical research. A graduate of the Albert Einstein College of Medicine and Williams College, Erol Onel currently serves as the Vice President of Heron Therapeutics in California. Outside of his professional work, Dr. Onel is an active philanthropist who donates to organizations such as the American Heart Association and Goodwill.
Founded in 1902, Goodwill is a nonprofit organization that provides employment opportunities, skills training, and education to enhance the dignity and life quality of individuals. Currently, the organization works towards its mission through a network of 162 independent Goodwill operations that provide employment support and local programming to individuals in need.
Goodwill’s achievements include:
-In 2015, assisted over 300,000 individuals to gain career and skills training through employment.
-In 2015, provided credentials to over 42,000 individuals to increase their total lifetime earnings potential by 14.2 billion dollars.
-Provided services to an all time total of over 37 millions individuals, including two million who utilized career services and 35 million who accessed virtual training via mobile devices and computers.
In 2016, the organization achieved a number one ranking among brands doing the most good worldwide by the Brand World Value Index.
Tuesday, May 9, 2017
The vice president of Heron Therapeutics, physician Erol Onel has built a successful career in the medical and pharmaceutical industries. In his position, he provides scientific leadership to the company and its team of professionals as they seek approval for a long-acting non-opioid pain drug. Over the years, Erol Onel has belonged to numerous organizations, including the American Medical Association.
A recent announcement from the American Medical Association (AMA) shared the organization’s hope for combating the opioid epidemic in the United States. The statement was released in response to a new strategy put forth by Health and Human Services (HHS). This new strategy was outlined during the National Rx Drug Abuse & Heroin Summit, and involves using a $485 million grant to fund treatment and prevention activities within the various states.
Many of the strategies outlined by the HHS fall in line with the AMA’s continual efforts to reduce opioid use through a dedicated task force. The organization’s Task Force to Reduce Opioid Abuse encourages physicians to use a prescription drug monitoring program (PDMP) to inform prescribing decisions. It also helps patients secure their prescriptions safely, improves physician education, and works to remove the stigma surrounding substance use disorders. These points were also presented during the Rx Summit by AMA board chair Patrice A. Harris, MD.